SecBot SecBot

ARMP

Armata Pharmaceuticals, Inc.
NYSE· Biological Products, (No Diagnostic Substances)· Inc. WA· CIK 0000921114 Biotech & Drug Discovery
$2.99 −0.88 (−22.74%)
Nov 16 4:00 PM ET · prev $3.87
Market cap
$140.2M
Micro cap
Consensus
Buy
88% Buy or better · 8 analysts
Median target
$17.50
+485% · range $15.00–20.00
Next earnings
Nov 18
in 2 days · EPS est. −$0.51
1 year
−55.4%
from $6.71 · Nov 17
30 days
−2.6%
from $3.07
52-week range
$2.78–14.80
−80% from high · low Oct 14
Avg volume 20D
80.1K
shares / day
Short interest
912.6K
≈2.5% of shares · +1.4%
Days to cover
9.8
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 18, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 8 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    7 of 8 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.570 → −$0.510 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +1.4% to 912.6K shares. 9.8 days to cover, ≈2.5% of shares.

  • TrendRANGE

    20% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
STATE STREET CORPADD184,501$677.1K
UBS Group AGDOUBLED54,374$199.6K
RENAISSANCE TECHNOLOGIES LLCTRIM34,653$127.2K
BARCLAYS PLCADD5,122$18.8K
Russell Investments Group, Ltd.DOUBLED4,503$16.5K
FMR LLCDOUBLED1,415$5.2K
CITIGROUP INCNEAR_EXIT589$2.2K
SIMPLEX TRADING, LLCNEAR_EXIT183$671.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 88% rate it Buy or better
Strong Buy2Buy5Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +485%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 23, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 10, 2026
Birx Deborah
Chief Executive Officer
Jul 10, 2026
TAX W/H$59.8K
Apr 24, 2026
Gilmer Daniel B.
Director
Apr 24, 2026
AWARD51,280 sh
Mar 14, 2026
Kyme Pierre
Chief Business Officer
Mar 14, 2026
TAX W/H$10.9K
Mar 14, 2026
Birx Deborah
Chief Executive Officer
Mar 14, 2026
TAX W/H$51.8K
Mar 9, 2026
Schlesinger Sarah J.
Director
Mar 9, 2026
AWARD25,640 sh
Mar 9, 2026
Kyme Pierre
Chief Business Officer
Mar 9, 2026
AWARD183,142 sh
Mar 9, 2026
Odysseas Kostas D
Director
Mar 9, 2026
AWARD25,640 sh
Mar 9, 2026
PATTI JOSEPH M
Director
Mar 9, 2026
AWARD25,640 sh

Earnings setup

Estimates
Nov 18
reports in 2 days
−$0.51
EPS estimate, this quarter
+11%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.51-$0.51–-$0.51-27.5%$0.00
Next QNoneNoneNo data$0.00
Current FY-$1.46-$1.46–-$1.46+21.7%$3.3M
Next FY-$1.39-$1.92–-$0.85+4.2%$2.8M

Short side

FINRA· Oct 30, 2026
912,610
shares short
+1.4%
vs prior settlement
9.8
days to cover
≈2.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Armata Pharmaceuticals reported Q3 2026 GAAP net income of $54.9M ($1.15 basic EPS, $(0.24) diluted EPS), driven by a…
PRESS-RELEASE · Impact 5/10
Nov 12, 2026 Earnings
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
LOS ANGELES, Nov. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arma
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
184,501 shares ($677.1K)
Sep 30, 2026 Inst.
UBS Group AG · DOUBLED
54,374 shares ($199.6K)
Sep 23, 2026 SEC
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to…
8-K · Impact 5/10
Sep 14, 2026 SEC
Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous phage therapy for…
8-K · Impact 7/10
Jul 10, 2026 Insider
Birx Deborah surrendered for taxes 14,041 shares
Chief Executive Officer @ $4.26 ($59.8K)
Apr 24, 2026 Insider
Gilmer Daniel B. was granted 51,280 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Upcoming
Recent
Nov 12, 2026
Earnings
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
LOS ANGELES, Nov. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage…
Sep 10, 2026
Press release
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage…
Sep 3, 2026
Press release
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage…
Aug 18, 2026
Earnings date
ARMP Q2 2026 Earnings Scheduled, 2026-08-18
Aug 12, 2026
Earnings
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage…

SecBot reports

6 filings · 3 bullish · 1 bearish · 2 neutral
All ARMP filing & press-release reports (6)